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Osteoid osteoma (OO) is defined as a benign bone-
forming tumour characterized by small size, limited 
growth potential and disproportionate pain (WHO, 
2002). Usually, OO is solitary, although the literature 
shows few reports of multiples lesions in the same 
patient, but not concomitant. 
In most cases, OO patients complain of severe 
nocturnal pain that usually responds to salicylates nd 
nonsteroidal anti-inflammatory drugs (NSAIDs). The 
exact mechanism of the pain in OO and why it is more 
intense at night is still unknown. Some reports have 
shown that the nidus is responsible for the severe pain, 
as evidenced by the disappearance of pain when the 
nidus is completely excised, and that prostaglandins 
seem to play a major role. Prostaglandin E2 is believ d 
to prompt vasodilation and pain. An increase 
concentration of prostaglandin has been found in the 
nidus of the lesion, as well as, a strong positivity for 
cyclooxy-genase-2 (a key enzyme in the production of 
prostaglandins, particularly prostaglandin E2). 
Clinics and pathology 
Etiology 
The pathogenesis of OO remains controversial. Some 
hypotheses have been reported: 
OO is a real neoplasm; OO is a reactive process that 
arises on an inflammatory basis, OO is an unusual 
healing and reparative process. However, this tumour 
does not enlarge, seldom exceeds 1cm in greatest 
diameter; and in some cases, spontaneous regression 
and healing occur. Contrary to typical neoplasms, the 
nidus of OO contains a relatively immature central area 
with more mature calcified peripheral bone. 
 
Osteoid Osteoma. Showing dense surrounding reactive 
sclerotic bone. 
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Osteoid Osteoma is characterized by anastomosing woven bone trabeculae, rimmed by a single layer of prominent osteoblast. 
 
Epidemiology 
OO is the third most common benign bone tumor. Its 
incidence is 11% among the benign tumors and 3% 
among all primary bone tumors. It is most common in 
the second and third decades. There is a male to female 
preponderance of 3 to 1. 
The majority of the OO cases occur in lower extremity 
of long bones, particularly in the proximal femur. In the 
spine, they almost exclusively occur in the posterior 
vertebral elements. Additionally, OOs may occur in a 
juxtaarticular bone within a synovial cavity where th y 
are termed intraarticular OOs. They are typically 
located in diaphyseal or metaphyseal cortices, but may
rarely be located in the medullary cavity or periosteum. 
Infrequently, they are seen in the epiphysis. 
Clinics 
Characteristically, patients complain of localized pain, 
generally worse at night and relieved with salicylates. 
This classic presentation is not always present and, 
however, night pain may be observed with other bone 
tumours. More importantly, virtually all patients have 
progressive pain. 
The natural history of untreated OO is toward 
spontaneous regression, it is taken an average of 6
years. During this period, the nidus gradually begins to 
calcify; afterwards, ossify, and, finally, blends into 
sclerotic surrounding bone. The local pain gradually 
diminishes. 
Indication for surgery depends on symptom severity 
and the patient's pain tolerance. With surgical resection, 
it has been emphasized that nidus removal is essential 
for pain relief. 
Familial occurrence of OO is an exceedingly rare 
event. The literature has reported only two descrip-
tions of OO occurring in two siblings (Kaye and 
Arnold, 1977; Kalil and Antunes, 2003). 
Pathology 
Morphologically, OO is a well-circumscribed lesion, 
consisting of a central area of woven bone trabeculae 
and osteoid, lined by a prominent single layer of plump 
osteoblast, and an intervening hypocellular but highly 
vascular stroma. The bone trabeculae are irregularly 
arranged and thin. Hyaline cartilage is not present. 
Osteoclasts may be distributed randomly throughout 
the lesion. Significant mitotic activity is usually absent 
and, when preset, limited to the stromal cells. Mature 
OO may be composed virtually entirely of compact 
woven bone. In all cases, the nidus is sharply 
demarcated from the surrounding, generally sclerotic 
bone. 
The nidus of OO usually has 1.5 to 2 cm in size and
consists of osteoid, osteoblasts, and variable amounts 
of fibrovascular stroma. 
O'Connell et al., in 1998, reported that 25 of 34 cases 
of OO contained phosphorylated neuro-filament, -
neurofilament-, and/or S-100-positive nerve fibers in 
the reactive zone around the nidus and/or in the nidus. 
The nerve fibers were larger and more abundant in the 
reactive zone than in the nidus, and they were 
occasionally visible on HE-stained slides, on 
retrospective review. None of the control "bone 
tumours" (e.g., osteoblastomas, osteosarcomas, giant
cell tumours) had detectable nerve fibers either within 
their substance or within the surrounding bone. 
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Treatment 
After radiographic and surgical localization, the nidus 
should be removed in its entirety. 
Prognosis 




Baruffi et al., in 2001, described the cytogenetic 
analysis of cells derived from two OO. The first tumour 
showed del(22)(q13.1) as the sole clonal chromosome 
alteration. The same alteration was present in the 
second OO, as a non-clonal entity. The authors 
mentioned that structural chromosomal alterations 
involving 22q13.1 in OO may affect critical genes 
involved in the regulation of cell proliferation, such as 
the YWHAH gene that codes for a 14-3-3 family 
members, dimeric phospho-serine-binding proteins that 
participate in signal transduction and checkpoint 
control pathways. Their primary function in mammals 
is to inhibit apoptosis. They also described that another 
gene mapped in this region is PDGFB that codes for a 
platelet-derived growth factor, a beta polypeptide 
(simian sarcoma viral [v-sis] oncogene homolog), a 
potent mitogen for cells of mesenchymal origin, also 
involved in the transformation process. 
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